Study Summary
This trial will test whether the drug Pembrolizumab can help people with NSCLC and untreated brain metastasis live longer with fewer side effects.
- Lung Cancer
- Cancer
- Cancer Brain Metastases
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: 12 months (Baseline, 3 months post-enrollment, 6 months post-enrollment, 9 months post-enrollment, 12 months post enrollment)
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
1 Treatment Group
Pembrolizumab with standard of care chemotherapy treatment
1 of 1
Experimental Treatment
45 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 85 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there still openings in this experiment for participants?
"Yes, according to clinicaltrials.gov the trial is actively recruiting participants. It was initially posted on December 7th 2021 and updated most recently on January 18th 2022. The study requires 45 patients from 1 medical centre." - Anonymous Online Contributor
What indications are typically treated with Pembrolizumab?
"Pembrolizumab is predominantly utilised to combat malignant tumours, but it has also been proven effective in treating unresectable melanoma, microsatellite instability high and locally advanced non-squamous non-small cell lung cancer." - Anonymous Online Contributor
What potential adverse effects may be associated with Pembrolizumab?
"After careful consideration, the team at Power ascertained that Pembrolizumab's safety is rated a 2. This rating suggests that there is some evidence of its security but not yet any verification regarding efficacy." - Anonymous Online Contributor
Who qualifies to partake in this experiment?
"This trial is recruiting 45 individuals aged 18 to 85 suffering from malignancies. To be eligible, they must demonstrate acceptable organ and marrow function, have non-small cell lung cancer with untreated asymptomatic brain metastases that lack oncogenic driver mutations, display no new neurological symptoms, possess fewer than ten intracranial lesions of size three centimeters or less each, expect a life expectancy of over three months, and understand their consent document before signing it." - Anonymous Online Contributor
Does this research include participants aged under 30?
"According to the study's inclusion criteria, individuals aged 18 and above but under 85 are eligible for enrolment." - Anonymous Online Contributor
What is the amount of participants in this experiment?
"Affirmative. Per the information available on clinicaltrials.gov, this research study is still recruiting participants and was first posted on December 7th 2021 with its most recent update occurring January 18th 2022. This trial requires 45 patients from 1 centre to participate." - Anonymous Online Contributor